These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37522644)

  • 1. Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review.
    Molina-Linde JM; Cordero-Pereda D; Baños-Álvarez E; Rosario-Lozano MP; Blasco-Amaro JA
    ESC Heart Fail; 2023 Oct; 10(5):2760-2772. PubMed ID: 37522644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review.
    Schmidt R; Rodrigues CG; Schmidt KH; Irigoyen MCC
    ESC Heart Fail; 2020 Feb; 7(1):3-14. PubMed ID: 31965746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
    Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
    J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
    Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
    Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
    Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baroreflex activation therapy for heart failure with reduced ejection fraction: A comprehensive systematic review and meta-analysis.
    Shi R; Sun T; Wang M; Xiang Q; Ding Y; Yin S; Chen Y; Shen L; Yu P; Chen X
    Heliyon; 2024 Jan; 10(2):e24177. PubMed ID: 38293445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
    Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise-based rehabilitation for heart failure.
    Taylor RS; Sagar VA; Davies EJ; Briscoe S; Coats AJ; Dalal H; Lough F; Rees K; Singh S
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD003331. PubMed ID: 24771460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction".
    Oliveira M
    Rev Port Cardiol; 2015 Dec; 34(12):795-7. PubMed ID: 27099884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
    Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
    Halbach M; Abraham WT; Butter C; Ducharme A; Klug D; Little WC; Reuter H; Schafer JE; Senni M; Swarup V; Wachter R; Weaver FA; Wilks SJ; Zile MR; Müller-Ehmsen J
    Int J Cardiol; 2018 Sep; 266():187-192. PubMed ID: 29705650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
    Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
    Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of baroreflex activation therapy for heart failure: A meta-analysis of randomized controlled trials.
    Cai G; Guo K; Zhang D; Qin S
    Medicine (Baltimore); 2020 Nov; 99(45):e22951. PubMed ID: 33157936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivabradine as adjuvant treatment for chronic heart failure.
    Benstoem C; Kalvelage C; Breuer T; Heussen N; Marx G; Stoppe C; Brandenburg V
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013004. PubMed ID: 33147368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on Baroreflex Activation Therapy and Vagus Nerve Stimulation for Treatment of Heart Failure With Reduced Ejection Fraction.
    Babar N; Giedrimiene D
    Cardiol Res; 2022 Feb; 13(1):11-17. PubMed ID: 35211219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure.
    Lindenfeld J; Gupta R; Grazette L; Ruddy JM; Tsao L; Galle E; Rogers T; Sears S; Zannad F
    JACC Heart Fail; 2021 Jun; 9(6):430-438. PubMed ID: 33992562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients.
    Mann JA; Abraham WT
    Curr Heart Fail Rep; 2019 Feb; 16(1):38-46. PubMed ID: 30762177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
    Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
    Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety and efficacy of Zhenwu decoction as adjuvant therapy for the treatment of heart failure with reduced ejection fraction: A protocol for systematic review and meta-analysis.
    Han Y; Huang L; Zhong G; Chang X; Zhu Q; Xu M; Mingtai C; Men L; Wang L
    Medicine (Baltimore); 2022 Jan; 101(4):e28672. PubMed ID: 35089212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.